Novartis Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
Jun 17, 2020
- FDA approval for Cosentyx??is based on the Phase III?PREVENT trial,??demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis (axSpA) disease spectrum
- There are an estimated 2.7M people living with axial spondyloarthritis (axSpA) in the US; however, it remains significantly underdiagnosed1,2
- nr-axSpA approval is the fourth indication for Cosentyx, which is backed by five years of clinical data supporting long-term safety and efficacy across moderate to severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)3-8
# # #
Novartis Media Relations E-mail:?media.relations@novartis.comAntonio Ligi Novartis Global External Communications +41 61 324 1374 (direct) antonio.ligi@novartis.comEric Althoff Novartis US External Communications +1 646 438 4335 eric.althoff@novartis.com | Louise Clark Novartis Pharma Communications +41 61 324 2970 (direct) louise.clark@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 778 5052 |
Thomas Hungerbuehler | +41 61 324 8425 | Cory Twining | +1 862 778 3258 |
Isabella Zinck | +41 61 324 7188 |